Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy. (April 2017)

• Record Type: Journal Article
• Authors: Zhang, Jing; Wang, Tianqi; Mu, Shengjun; Olerile, Livesey D; Yu, Xiaoyue; Zhang, Na
• Is Part Of: Nanomedicine. Volume 12:Number 8(2017)
• Page Start: 911
• Page End: 925
• Publication Date: 2017-04
• Subjects: biomacromolecule/lipid hybrid nanoparticles -- enzyme-responsive -- HCC -- hyaluronic acid -- sorafenib; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2016-0402
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: Hybrids composed of various materials are highly versatile for drug delivery in tumor therapy including hepatocellular carcinoma. Herein, a sorafenib (SF)-loaded biomacromolecule hyaluronic acid (HA)/lipid hybrid nanoparticles (HA/SF-cLNS) were developed for targeting drug delivery.Materials & methods: In vitro assays determined HA/SF-cLNS release behavior, enzymatic degradation, uptake and cytotoxicity. H22-bearing liver cancer xenograft murine models were used to evaluate the biodistribution and therapeutic efficacy in vivo .Results: HA/SF-cLNS could be disassembled and drug was released in response to hyaluronidase. In vivo imaging results demonstrated HA/cLNS could enhance drug accumulation at tumor site. Meanwhile, HA/SF-cLNS exhibited improved antitumor efficacy in vitro and in vivo .Conclusion: HA/SF-cLNS demonstrated the potential to enhance antitumor efficacy of SF.